S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Regulus Expands its Biomarkers Platform and Establishes Regulus microMarkers™, a New R&D Division Focused on Identifying microRNAs as Biomarkers of Disease (2014/1/13)|
|Regulus Appoints Head of Regulus microMarkers™ R&D Division (2014/2/13)|
|Regulus Presents Positive Preclinical Data on miR-21 and miR-221 Oncology Programs In Oral and Poster Presentations at AACR 2014 Annual Meeting (2014/4/7)|
|Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights (2013/11/13)|
|Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights (2013/8/13)|
|Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome ()|
|Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target (2013/10/28)|
|Positive Preclinical Profile of RG-101, a GalNAc-conjugated anti-miR Targeting microRNA-122, Supports Clinical Development for the Treatment of HCV (2013/11/4)|
|Regulus to Present at 32nd Annual J.P. Morgan Healthcare Conference ()|
|Regulus Announces Timing for Fourth Quarter and Year-End 2013 Financial Results Webcast and Conference Call (2014/2/20)|
Click above to view more mutual fund data and stats for rgls - Regulus Therapeutics Inc.